Borthwick-Duffy SA Epidemiology and prevalence of psychopathology in people with mental retardation. J Consult Clin Psychol. 1994 Feb;62(1):17-27. doi: 10.1037//0022-006x.62.1.17.
Briggs AM, Fisher WW, Greer BD, Kimball RT Prevalence of resurgence of destructive behavior when thinning reinforcement schedules during functional communication training. J Appl Behav Anal. 2018 Jul;51(3):620-633. doi: 10.1002/jaba.472. Epub 2018 May 17.
Fuhrman AM, Greer BD, Zangrillo AN, Fisher WW Evaluating competing activities to enhance functional communication training during reinforcement schedule thinning. J Appl Behav Anal. 2018 Oct;51(4):931-942. doi: 10.1002/jaba.486. Epub 2018 Jun 29.
Greer BD, Fisher WW, Saini V, Owen TM, Jones JK Functional communication training during reinforcement schedule thinning: An analysis of 25 applications. J Appl Behav Anal. 2016 Mar;49(1):105-21. doi: 10.1002/jaba.265. Epub 2015 Oct 20.
Greer BD, Shahan TA Resurgence as Choice: Implications for promoting durable behavior change. J Appl Behav Anal. 2019 Jul;52(3):816-846. doi: 10.1002/jaba.573. Epub 2019 May 3.
Hagopian LP, Boelter EW, Jarmolowicz DP Reinforcement schedule thinning following functional communication training: review and recommendations. Behav Anal Pract. 2011 Summer;4(1):4-16. doi: 10.1007/BF03391770.
Hagopian LP, Fisher WW, Sullivan MT, Acquisto J, LeBlanc LA Effectiveness of functional communication training with and without extinction and punishment: a summary of 21 inpatient cases. J Appl Behav Anal. 1998 Summer;31(2):211-35. doi: 10.1901/jaba.1998.31-211.
Miller SA, Fisher WW, Greer BD, Saini V, Keevy MD Procedures for determining and then modifying the extinction component of multiple schedules for destructive behavior. J Appl Behav Anal. 2022 Mar;55(2):463-480. doi: 10.1002/jaba.896. Epub 2021 Dec 12.
Mitteer DR, Greer BD, Randall KR, Haney SD On the scope and characteristics of relapse when treating severe destructive behavior. J Appl Behav Anal. 2022 Jun;55(3):688-703. doi: 10.1002/jaba.912. Epub 2022 Mar 15.
Muething C, Pavlov A, Call N, Ringdahl J, Gillespie S Prevalence of resurgence during thinning of multiple schedules of reinforcement following functional communication training. J Appl Behav Anal. 2021 Apr;54(2):813-823. doi: 10.1002/jaba.791. Epub 2020 Oct 25.
Rooker GW, Jessel J, Kurtz PF, Hagopian LP Functional communication training with and without alternative reinforcement and punishment: an analysis of 58 applications. J Appl Behav Anal. 2013 Dec;46(4):708-22. doi: 10.1002/jaba.76. Epub 2013 Aug 22.
Shahan TA, Browning KO, Nall RW Resurgence as Choice in Context: Treatment duration and on/off alternative reinforcement. J Exp Anal Behav. 2020 Jan;113(1):57-76. doi: 10.1002/jeab.563. Epub 2019 Nov 27.
Shahan TA, Browning KO, Nist AN, Sutton GM Resurgence and downshifts in alternative reinforcement rate. J Exp Anal Behav. 2020 Sep;114(2):163-178. doi: 10.1002/jeab.625. Epub 2020 Aug 27.
Shahan TA, Craig AR Resurgence as Choice. Behav Processes. 2017 Aug;141(Pt 1):100-127. doi: 10.1016/j.beproc.2016.10.006. Epub 2016 Oct 26.
Shahan TA, Greer BD Destructive behavior increases as a function of reductions in alternative reinforcement during schedule thinning: A retrospective quantitative analysis. J Exp Anal Behav. 2021 Sep;116(2):243-248. doi: 10.1002/jeab.708. Epub 2021 Jul 4.
Motivational Refinements for Facilitating Reinforcement Schedule Thinning
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
